Drug intelligence / Profile preview

Rhea-003

Development stage: Preclinical
Lead developer: Rhea Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Rhea-003 is a lead small-molecule compound being developed by Rhea Pharmaceuticals as a topical agent for the treatment of both fungal and bacterial skin infections. Discovered using artificial intelligence technology, the compound is designed to address multi-drug resistant (MDR) microbial pathogens through a novel mechanism of action. Rhea Pharmaceuticals, a Singapore-based biopharmaceutical company, is part of the Charoen Pokphand Indonesia Group/Central Proteina Prima Group. The drug is currently in the discovery phase of development, and its specific molecular target has not yet been publicly disclosed.

Beyond the preview

Go deeper on Rhea-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhea-003.

Explore the full profile